Biomea Fusion Inc expected to post a loss of 61 cents a share - Earnings Preview
30/04/2025 21:02
Biomea Fusion Inc BMEA.OQ BMEA.O is expected to show no change in quarterly revenue when it reports results on May 2 (estimated) for the period ending March 31 2025 LSEG's mean analyst estimate for Biomea Fusion Inc is for a loss of 61 cents per share. The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell." The mean earnings estimate of analysts was unchanged in the last three months. Wall Street's median 12-month price target for Biomea Fusion Inc is $22.00, above its last closing price of $2.20. Previous quarterly performance (using preferred earnings measure in US dollars).
| QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
| Dec. 31 2024 | -0.92 | -0.81 | Beat | 12.1 | |
| Sep. 30 2024 | -0.91 | -0.95 | -0.91 | Beat | 4.2 |
| Jun. 30 2024 | -1.07 | -1.07 | -1.03 | Beat | 3.8 |
| Mar. 31 2024 | -0.99 | -0.99 | -1.09 | Missed | -9.6 |
| Dec. 31 2023 | -0.82 | -0.85 | -0.98 | Missed | -15.1 |
| Sep. 30 2023 | -0.82 | -0.82 | -0.80 | Beat | 2.8 |
| Jun. 30 2023 | -0.90 | -0.88 | -0.70 | Beat | 20 |
| Mar. 31 2023 | -0.82 | -0.81 | -0.98 | Missed | -20.9 |
Recent news on Biomea Fusion
See all newsUS RESEARCH ROUNDUP-BlackRock, Microsoft, TransDigm Group
Brief: Biomea Fusion Announces Phase 1 Results For Bmf-650, Its Investigational Next-Generation Oral Small Molecule Glp-1 Receptor Agonist
Brief: Biomea Fusion To Announce Phase I Results For Bmf-650, Its Next-Generation Oral Small-Molecule Glp-1 Receptor Agonist
Brief: Biomea Fusion Announces Termination Of Proposed Public Offering Of Securities
Brief: Biomea Fusion Announces Completion Of Enrollment In Covalent-211 Phase Ii Trial Of Icovamenib In Insulin-Deficient Type 2 Diabetes